Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE3.2600
- TODAY'S CHANGE (%)0.1500 (4.8232%)
- Bid / Lots3.2700/ 2
- Ask / Lots3.3100/ 20
- Open / Previous Close3.1600 / 3.1100
- Day Range
- 52 Week Range
- Volume855,585
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 3586 | 3.17 |
| 09:34 ET | 100 | 3.19 |
| 09:36 ET | 1100 | 3.18 |
| 09:38 ET | 100 | 3.18 |
| 09:39 ET | 1350 | 3.185 |
| 09:41 ET | 1600 | 3.2 |
| 09:43 ET | 1800 | 3.19 |
| 09:45 ET | 1530 | 3.17 |
| 09:48 ET | 940 | 3.17 |
| 09:50 ET | 911 | 3.17 |
| 09:52 ET | 51148 | 3.215 |
| 09:54 ET | 2396 | 3.2155 |
| 09:56 ET | 200 | 3.22 |
| 09:57 ET | 6300 | 3.215 |
| 09:59 ET | 1900 | 3.215 |
| 10:01 ET | 2395 | 3.21 |
| 10:03 ET | 3395 | 3.2102 |
| 10:06 ET | 900 | 3.215 |
| 10:08 ET | 1400 | 3.225 |
| 10:10 ET | 920 | 3.23 |
| 10:12 ET | 4699 | 3.24 |
| 10:14 ET | 32148 | 3.22 |
| 10:15 ET | 6967 | 3.2 |
| 10:17 ET | 10749 | 3.2083 |
| 10:19 ET | 4001 | 3.2 |
| 10:21 ET | 1562 | 3.2 |
| 10:24 ET | 3977 | 3.205 |
| 10:26 ET | 9871 | 3.21 |
| 10:28 ET | 600 | 3.2001 |
| 10:30 ET | 2779 | 3.205 |
| 10:32 ET | 9035 | 3.2 |
| 10:33 ET | 8308 | 3.2087 |
| 10:35 ET | 8895 | 3.22 |
| 10:37 ET | 13276 | 3.2401 |
| 10:39 ET | 1498 | 3.225 |
| 10:42 ET | 1500 | 3.23 |
| 10:44 ET | 200 | 3.23 |
| 10:46 ET | 1000 | 3.2325 |
| 10:48 ET | 100 | 3.24 |
| 10:50 ET | 100 | 3.235 |
| 10:51 ET | 966 | 3.235 |
| 10:53 ET | 1100 | 3.23 |
| 10:55 ET | 5500 | 3.23 |
| 10:57 ET | 852 | 3.2321 |
| 11:00 ET | 200 | 3.23 |
| 11:04 ET | 165 | 3.22 |
| 11:06 ET | 926 | 3.215 |
| 11:09 ET | 3998 | 3.2 |
| 11:11 ET | 2050 | 3.195 |
| 11:13 ET | 700 | 3.2 |
| 11:22 ET | 3000 | 3.195 |
| 11:27 ET | 3526 | 3.2 |
| 11:31 ET | 5885 | 3.1901 |
| 11:33 ET | 100 | 3.195 |
| 11:38 ET | 100 | 3.195 |
| 11:42 ET | 1100 | 3.195 |
| 11:45 ET | 300 | 3.2027 |
| 11:58 ET | 3600 | 3.2001 |
| 12:00 ET | 4616 | 3.195 |
| 12:02 ET | 400 | 3.185 |
| 12:05 ET | 647 | 3.188 |
| 12:09 ET | 1418 | 3.195 |
| 12:14 ET | 6546 | 3.205 |
| 12:16 ET | 2186 | 3.21 |
| 12:18 ET | 800 | 3.205 |
| 12:20 ET | 100 | 3.21 |
| 12:23 ET | 274 | 3.21 |
| 12:25 ET | 3999 | 3.2099 |
| 12:27 ET | 4092 | 3.21 |
| 12:30 ET | 1100 | 3.2 |
| 12:32 ET | 1997 | 3.22 |
| 12:34 ET | 1100 | 3.22 |
| 12:36 ET | 500 | 3.215 |
| 12:38 ET | 2850 | 3.2104 |
| 12:45 ET | 900 | 3.2111 |
| 12:54 ET | 3196 | 3.225 |
| 12:56 ET | 15827 | 3.23 |
| 12:57 ET | 200 | 3.235 |
| 12:59 ET | 1137 | 3.2318 |
| 01:01 ET | 3387 | 3.24 |
| 01:03 ET | 1391 | 3.25 |
| 01:06 ET | 325 | 3.25 |
| 01:08 ET | 2100 | 3.255 |
| 01:10 ET | 1350 | 3.26 |
| 01:12 ET | 100 | 3.26 |
| 01:15 ET | 1000 | 3.2506 |
| 01:17 ET | 500 | 3.2511 |
| 01:19 ET | 1931 | 3.25 |
| 01:21 ET | 1796 | 3.245 |
| 01:30 ET | 100 | 3.25 |
| 01:32 ET | 250 | 3.25 |
| 01:37 ET | 926 | 3.25 |
| 01:39 ET | 7500 | 3.26 |
| 01:44 ET | 2290 | 3.27 |
| 01:46 ET | 1245 | 3.27 |
| 01:48 ET | 5172 | 3.29 |
| 01:50 ET | 800 | 3.285 |
| 01:51 ET | 3622 | 3.29 |
| 01:53 ET | 5712 | 3.2916 |
| 01:55 ET | 10125 | 3.31 |
| 02:00 ET | 100 | 3.31 |
| 02:02 ET | 3084 | 3.3 |
| 02:04 ET | 2346 | 3.295 |
| 02:06 ET | 16949 | 3.33 |
| 02:08 ET | 100 | 3.33 |
| 02:09 ET | 300 | 3.32 |
| 02:11 ET | 7175 | 3.3391 |
| 02:13 ET | 6454 | 3.345 |
| 02:15 ET | 3504 | 3.32 |
| 02:18 ET | 100 | 3.315 |
| 02:22 ET | 8157 | 3.31 |
| 02:24 ET | 100 | 3.315 |
| 02:26 ET | 100 | 3.32 |
| 02:27 ET | 100 | 3.32 |
| 02:29 ET | 300 | 3.315 |
| 02:33 ET | 8120 | 3.3126 |
| 02:36 ET | 15252 | 3.285 |
| 02:38 ET | 1417 | 3.295 |
| 02:40 ET | 2106 | 3.2801 |
| 02:42 ET | 1080 | 3.285 |
| 02:44 ET | 940 | 3.3 |
| 02:45 ET | 200 | 3.3 |
| 02:47 ET | 1300 | 3.29 |
| 02:49 ET | 1000 | 3.29 |
| 02:51 ET | 200 | 3.29 |
| 02:54 ET | 200 | 3.29 |
| 02:56 ET | 2384 | 3.29 |
| 02:58 ET | 300 | 3.29 |
| 03:00 ET | 2151 | 3.2811 |
| 03:02 ET | 200 | 3.285 |
| 03:03 ET | 409 | 3.28 |
| 03:05 ET | 900 | 3.275 |
| 03:07 ET | 100 | 3.28 |
| 03:09 ET | 300 | 3.275 |
| 03:12 ET | 57388 | 3.24 |
| 03:14 ET | 2316 | 3.26 |
| 03:16 ET | 5427 | 3.26 |
| 03:18 ET | 1923 | 3.26 |
| 03:20 ET | 1260 | 3.26 |
| 03:21 ET | 1872 | 3.25 |
| 03:25 ET | 300 | 3.26 |
| 03:27 ET | 828 | 3.2547 |
| 03:30 ET | 1000 | 3.255 |
| 03:32 ET | 14217 | 3.26 |
| 03:34 ET | 5089 | 3.26 |
| 03:36 ET | 12484 | 3.25 |
| 03:38 ET | 10500 | 3.255 |
| 03:39 ET | 13934 | 3.255 |
| 03:41 ET | 1115 | 3.255 |
| 03:43 ET | 17831 | 3.245 |
| 03:45 ET | 51958 | 3.24 |
| 03:48 ET | 11239 | 3.245 |
| 03:50 ET | 10575 | 3.26 |
| 03:52 ET | 9506 | 3.25 |
| 03:54 ET | 31805 | 3.25 |
| 03:56 ET | 25688 | 3.24 |
| 03:57 ET | 39831 | 3.265 |
| 03:59 ET | 6942 | 3.26 |
Apr 10, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $6.00/Share by Needham, from 6:21AM ET on Wednesday Apr 10, 2024 by Dow Jones
6:21AM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 457.3M | -12.4x | --- |
Arrivent Biopharma Inc | 577.1M | -7.9x | --- |
Cabaletta Bio Inc | 579.9M | -7.5x | --- |
Compass Pathways PLC | 583.0M | -3.6x | --- |
Aerovate Therapeutics Inc | 583.1M | -7.1x | --- |
Oculis Holding AG | 533.1M | 0.0x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $457.3M |
|---|---|
Revenue (TTM) | $8.9M |
Shares Outstanding | 140.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-0.26 |
Book Value | $0.62 |
P/E Ratio | -12.4x |
Price/Sales (TTM) | 51.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -444.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
